Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia
A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia
Status: Enrolling
Updated:  3/12/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia
A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia
Status: Enrolling
Updated: 3/12/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission
Phase II Study of Pidilizumab (MDV9300) in Patients With Diffuse Large B-Cell Lymphoma Following First Remission
Status: Enrolling
Updated:  3/13/2018
Georgia Regents University Medical Center
mi
from
Augusta, GA
Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission
Phase II Study of Pidilizumab (MDV9300) in Patients With Diffuse Large B-Cell Lymphoma Following First Remission
Status: Enrolling
Updated: 3/13/2018
Georgia Regents University Medical Center
mi
from
Augusta, GA
Click here to add this to my saved trials
Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission
Phase II Study of Pidilizumab (MDV9300) in Patients With Diffuse Large B-Cell Lymphoma Following First Remission
Status: Enrolling
Updated:  3/13/2018
Northwestern University
mi
from
Chicago, IL
Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission
Phase II Study of Pidilizumab (MDV9300) in Patients With Diffuse Large B-Cell Lymphoma Following First Remission
Status: Enrolling
Updated: 3/13/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma
A Single Arm Pilot Study of Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  3/13/2018
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma
A Single Arm Pilot Study of Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 3/13/2018
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
Status: Enrolling
Updated:  3/14/2018
Massachusetts General Hospital
mi
from
Boston, MA
Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
Status: Enrolling
Updated: 3/14/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
Status: Enrolling
Updated:  3/14/2018
Massachusetts General Hospital
mi
from
Boston, MA
Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
Status: Enrolling
Updated: 3/14/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Imaging of Lymphatic Anomalies
Dynamic Contrast Enhanced MR Lymphangiogram Imaging of Lymphatic Anomalies (LA)
Status: Enrolling
Updated:  3/19/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Imaging of Lymphatic Anomalies
Dynamic Contrast Enhanced MR Lymphangiogram Imaging of Lymphatic Anomalies (LA)
Status: Enrolling
Updated: 3/19/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Advocate Illinois Masonic Medical Center
mi
from
Chicago, IL
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Advocate Illinois Masonic Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Baylor Sammons Cancer Center
mi
from
Dallas, TX
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Baylor Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Cancer Center of Central Connecticut
mi
from
Southington, CT
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Cancer Center of Central Connecticut
mi
from
Southington, CT
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Compassionate Cancer Care Medical Group INC
mi
from
Corona, CA
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Compassionate Cancer Care Medical Group INC
mi
from
Corona, CA
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Kentucky Cancer Clinic
mi
from
Hazard, KY
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Kentucky Cancer Clinic
mi
from
Hazard, KY
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Lalita Pandit, MD, Inc.
mi
from
Fountain Valley, CA
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Lalita Pandit, MD, Inc.
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Memorial Hospital
mi
from
Colorado Springs, CO
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Memorial Hospital
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Newland Medical Associates
mi
from
Southfield, MI
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Newland Medical Associates
mi
from
Southfield, MI
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Sanford Roger Maris Cancer Center
mi
from
Fargo, ND
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Sanford Roger Maris Cancer Center
mi
from
Fargo, ND
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Santa Monica Hematology/Oncology
mi
from
Los Angeles, CA
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Santa Monica Hematology/Oncology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
The Cancer Center, Hackensack University Medical Center
mi
from
Hackensack, NJ
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
The Cancer Center, Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
University Cancer Institute, LLC
mi
from
Boynton Beach, FL
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
University Cancer Institute, LLC
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
University of Kentucky
mi
from
Lexington, KY
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Virginia Cancer Institute
mi
from
Richmond, VA
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Virginia Cancer Institute
mi
from
Richmond, VA
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Ironwood Cancer and Research Center
mi
from
Chandler, AZ
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Ironwood Cancer and Research Center
mi
from
Chandler, AZ
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Providence St Joseph Medical Center/Cancer Center
mi
from
Burbank, CA
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Providence St Joseph Medical Center/Cancer Center
mi
from
Burbank, CA
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Saint Jude Heritage Medical Center
mi
from
Fullerton, CA
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Saint Jude Heritage Medical Center
mi
from
Fullerton, CA
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Florida Cancer Specialists
mi
from
Englewood, FL
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Florida Cancer Specialists
mi
from
Englewood, FL
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Saint Joseph Medical Center
mi
from
Westminster, MD
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Saint Joseph Medical Center
mi
from
Westminster, MD
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Mass General Hospital
mi
from
Boston, MA
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Mass General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
The Cancer Center at Hackensack University Medical Center
mi
from
Cherry Hill, NJ
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
The Cancer Center at Hackensack University Medical Center
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Hematology Oncology Associates of NJ
mi
from
Morristown, NJ
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Hematology Oncology Associates of NJ
mi
from
Morristown, NJ
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Somerset Hematology-Oncology Associates
mi
from
Somerset, NJ
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Somerset Hematology-Oncology Associates
mi
from
Somerset, NJ
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
The Cancer Center at Hackensack University Medical Center
mi
from
Sparta, NJ
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
The Cancer Center at Hackensack University Medical Center
mi
from
Sparta, NJ
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
St. Luke's Roosevelt Hospital
mi
from
New York, NY
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
St. Luke's Roosevelt Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
M.D. Anderson Cancer Center
mi
from
Houston, TX
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Joe Arrington Cancer Center
mi
from
Lubbock, TX
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Joe Arrington Cancer Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
National Cancer Center Hospital
mi
from
Chuo-ku,
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
National Cancer Center Hospital
mi
from
Chuo-ku,
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Orlando Health
mi
from
Orlando, FL
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Orlando Health
mi
from
Orlando, FL
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Florida Cancer Specialists
mi
from
Saint Petersburg, FL
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Florida Cancer Specialists
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated:  3/22/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Status: Enrolling
Updated: 3/22/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
Status: Enrolling
Updated:  3/23/2018
Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
Status: Enrolling
Updated: 3/23/2018
Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial
Status: Enrolling
Updated:  3/26/2018
VA Puget Sound Health Care System
mi
from
Seattle, WA
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial
Status: Enrolling
Updated: 3/26/2018
VA Puget Sound Health Care System
mi
from
Seattle, WA
Click here to add this to my saved trials
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial
Status: Enrolling
Updated:  3/26/2018
The Mayo Clinic
mi
from
Rochester, MN
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial
Status: Enrolling
Updated: 3/26/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial
Status: Enrolling
Updated:  3/26/2018
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial
Status: Enrolling
Updated: 3/26/2018
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial
Status: Enrolling
Updated:  3/26/2018
Rigshospitalet University Hospital
mi
from
Copenhagen,
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial
Status: Enrolling
Updated: 3/26/2018
Rigshospitalet University Hospital
mi
from
Copenhagen,
Click here to add this to my saved trials
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
Status: Enrolling
Updated:  3/26/2018
Massachusetts General Hospital
mi
from
Boston, MA
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
Status: Enrolling
Updated: 3/26/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials